Leverage AI to Lower Cost, Barriers to Cell Therapies
Off-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system’s rejection and navigating the FDA’s approval process are crucial challenges.
Could Semaglutide Offer An Alternative Solution to Opioid Use Disorder?
- Semaglutide, a GLP1-RA, shows promise in reducing opioid overdose risk by modulating dopamine reward signaling.
- Only 25% of individuals with OUD receive treatment, with nearly 50% discontinuing within six months.
Nobel Prize in Chemistry Awarded to Trio Who Cracked the Code of Proteins
Google DeepMind’s John Jumper and Demis Hassabis share honor with David Baker for transforming ability to understand human biology.
New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from the Inflation Reduction Act
New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation Reduction Act’s (IRA) drug pricing provisions. In fact, the study suggests some patients may pay more. In a research brief commissioned by We Work For Health with analysis performed by the IQVIA Institute for Human Data Science, researchers estimated what patients will actually pay for the 10 Part D medicines chosen by the Centers for Medicare and Medicaid Services for government price controls. The IQVIA Institute calculated how changes in Medicare coverage and other factors will impact patient out-of-pocket costs. The study reveals how unintended consequences of the law could lead to negative impacts for seniors, including increased costs and coverage barriers for certain medications.
Recently, I had the opportunity to connect with Amanda Scholz, UBC Senior Clinical Program Manager, to discuss how clinical adherence programs empower patients and bolster persistence to prescribed therapies. Tune into our recent podcast and listen on your lunch hour walk today! Pharmaceutical Commerce Magazine
https://lnkd.in/e5rZjSyC
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs